Search PubMed⌕ Search

Biomedical subjects

H Salomon

Publications and source records attributed to H Salomon.

50 records · Page 3Linked to original sources
PubMed1980

Lack of association between cancer incidence and residence near petrochemical industry in the San Francisco Bay area.

Estimated age-adjusted incidence rates for cancer during 1971--77 among Kaiser Foundation Health Plan (KFHP) members living in a portion of the San Francisco Bay area (SFBA) characterized by a heavy concentration of petroleum and chemical industries were compared to estimated rates among KFHP members in the remainder of the SFBA. One hundred fifty-four comparisons were done for 41 selected cancer sites. The number of significant differences did not appear inconsistent with what might be expected by chance alone; furthermore, in most of these instances the so-called exposed area showed the lower rate. These findings provided some assurance that place of residence near petrochemical industries is not associated with increased cancer risk.

Age Factors↗
PubMedDate not supplied

Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.

Resistant variants were selected in vitro against two novel nucleoside analogues, (+) dOTC and (-) dOTFC using the HIV-1 molecular clone HXB2D. The variants obtained displayed 6.5-fold and 10-fold resistance to these compounds, respectively. Cloning and sequencing of the RT genes of the selected viruses identified two mutations, M184I for (+) dOTC and M184V for (-) dOTFC. Results with mutated recombinant clones of HXB2D confirmed the importance of these mutations in MT-4 cells. The resistance profiles of clinical samples with wild-type or 3TC-resistant phenotypes were also studied; low to moderate levels of cross-resistance were observed against the novel compounds.

Anti-HIV Agents↗
PubMedDate not supplied

Antiviral activity and resistance profile of phosphazid--a novel prodrug of AZT.

Both AZT and its novel 5'-hydrogen phosphonate derivative, Phosphazid, possess similar in vitro activity and resistance profiles. Experiments involving AZT-resistant virus isolates revealed a strong correlation between resistance to AZT and cross-resistance to Phosphazid. In vitro selection for resistance to Phosphazid yielded viruses that were about 15-fold less sensitive than wild-type virus to this drug. Sequencing of the reverse transcriptase region of seven Phosphazid-selected viruses revealed a single codon mutation, D67N, that is associated with resistance to AZT.

Anti-HIV Agents↗
PubMedDate not supplied

Regression of AIDS-related Kaposi's sarcoma following combined antiretroviral treatment.

The aim of the study was to assess regression of Kaposi's sarcoma (KS) in AIDS patients in Argentina. Eighteen male AIDS patients with human immunodeficiency virus (HIV)-associated Kaposi's sarcoma at different clinical stages received KS specific treatment and/or anti-retroviral therapy. Triple anti-retroviral therapy was given to most of the patients with the exception of four who received zidovudine (ZDV) in combination with another nucleoside analogue but no protease inhibitors. Plasma viral load and CD4+ T lymphocyte number were measured in two blood samples (before and after treatment). Complete remission was found in all patients (five) at KS stage I, three out of eight patients at stage II but in none at stages III and IV. Two out of three patients at KS stage IV did not respond to treatments at all. Three patients at KS stages I and II showed complete remission of sarcoma with only anti-retroviral therapy suggesting that anti-retroviral therapy and non-KS specific chemotherapy can successfully control KS.

Acquired Immunodeficiency Syndrome↗